ADMA To Be Uplisted, VVUS Up After-Hours, NVAX For The Long Haul, CCXI On Watch

(RTTNews) - ADMA Biologics Inc.'s (ADMA.OB) common stock has been approved for listing on the NASDAQ Capital Market beginning on November 10, 2014 under the symbol "ADMA".

The company expects to provide top-line, preliminary results from its phase III clinical study of RI-002 for primary immune deficiency diseases by the end of this year.

RI-002 is a specialty plasma-derived, polyclonal, Intravenous Immune Globulin, or IGIV, derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, Cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies targeted to respiratory syncytial virus (RSV).

ChemoCentryx Inc. (CCXI) is scheduled to report 52-week phase II data of its investigational drug CCX140 in patients with diabetic nephropathy later this year.

The company is also expected to initiate a phase I oncology trial of CCX872 in patients with pancreatic cancer during this quarter and begin dosing in early 2015. Other events coming its way this quarter are the commencement of a phase II clinical trial with CCX168 in North America in patients with antibody-associated vasculitis and initiation of a phase II proof-of-concept clinical trial with CCX168 in patients with atypical hemolytic uremic syndrome (aHUS).

CCXI closed Wednesday's trading at $5.53, unchanged from the previous day's close.

Novavax Inc. (NVAX) has a couple of events to watch out for this quarter and in the next year.

During this quarter, the company plans to initiate - a phase I clinical trial of its RSV F Vaccine in pediatric subjects; a phase II clinical trial of its seasonal quadrivalent influenza VLP vaccine candidate in healthy adult subjects; and a phase I study of its Ebola GP Vaccine.

A phase II clinical trial of its RSV F Vaccine in 1,600 elderly subjects is underway, with safety and efficacy data expected in the third quarter of 2015.

Another ongoing phase II trial is that of the investigational RSV F Vaccine in healthy women in their third trimester of pregnancy. The safety, immunogenicity and transplacental antibody transfer data from this clinical trial is expected in the third quarter of 2015.

NVAX closed Wednesday's trading at $5.13, down 7.57%. In after-hours, the stock gained 2.34% to $5.25.

Shares of VIVUS Inc. (VVUS) were up more than 4 percent in extended trading Wednesday following encouraging obesity drug revenue numbers.

According to the company, the reimbursement environment for its obesity drug Qsymia has been improving and the net revenue per prescription has been increasing. Net product revenue in Q3, 2014 is $12.5 million from sales of Qsymia, compared to $6.4 million for the third quarter of 2013.

VVUS closed Wednesday's trading at $3.30, down 2.23%. In after-hours, the stock rose 4.40% to $3.44.